Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 660-667

  Ogino, Hirokazu ^a   Yano, Seiji ^a,b   Kakiuchi, Soji ^a   Muguruma, Hiroaki ^a   Ikuta, Kenji ^a   Hanibuchi, Masaki ^a   Uehara, Hisanori ^a   Tsuchida, Kunihiro ^a,c   Sugino, Hiromu ^a,d   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; FOLLISTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LUNG SMALL CELL CANCER; MALE; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; FOLLISTATIN; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, SCID; MICE, TRANSGENIC; NEOPLASM METASTASIS; TRANSFECTION; WOUND HEALING;

EID: 38949172092     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1221     Document Type: Article

References (44)

1. Chen YG, Lui HM, Lin SL, Lee JM, Ying SY. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med 2002;227:75-87.
2. Harrison CA, Gray PC, Vale WW, Robertson DM. Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 2005;16:73-8.
3. Robertson DM, Klein R, de Vos FL, et al. The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 1987;149:744-9.
4. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci U S A 1987;84:8282-6.
5. Nakamura T, Takino K, Eto Y, Shibai H, Titani K, Sugino H. Activin-binding protein from rat ovary is follistatin. Science 1990;247:836-8.
6. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death inmice deficient in follistatin. Nature 1995;374:360-3.
7. Minna JD, Kurie JM, Jacks T. A big step in the study of small cell lung cancer. Cancer Cell 2003;4:163-6.
8. Hoon DS, Kitago M, Kim J, et al. Molecular mechanisms of metastasis. Cancer Metastasis Rev 2006;25:203-20.
9. Yano S, Nishioka Y, Izumi K, et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996;67:211-7.
10. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000;12:209-17.
11. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
12. Kiura K, Watarai S, Shibayama T, Ohnoshi T, Kimura I, Yasuda T. Inhibitory effects of cholera toxin on in vitro growth of human lung cancer cell lines. Anticancer Drug Des 1993;8:417-28.
13. Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, Miyasaka M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin-2 receptor β chain monoclonal antibody in mice. J Exp Med 1993;178:1103-7.
14. Schwall RH, Lai C. Erythroid differentiation bioassays for activin. Methods Enzymol 1991;198:340-6.
15. Green LM, Reade JL, Ware CF. Rapid colometric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 1984;70:257-68.
16. Richards TS, Dunn CA, Carter WG, Usui ML, Olerud JE, Lampe PD. Protein kinase C spatially and temporally regulates gap junctional communication during human wound repair via phosphorylation of connexin43 on serine368. JCell Biol 2004;167:555-62.
17. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
18. Yano S, Muguruma H, Matsumori Y, et al. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 2005;11:8789-98.
19. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001;411:375-9.
20. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505.
21. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-3.
22. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
23. Yano S, Nishioka Y, Nokihara H, Sone S. Macrophage colony-stimulating factor gene transduction into human lung cancer cells differentially regulates metastasis formation in various organ microenvironments of natural killer cell-depleted SCID mice. Cancer Res 1997;57:784-90.
24. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99.
25. Mundy GR. Metastasis to bone: causes, consequences andt herapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
26. Zhang YQ, Kanzaki M, Shibata H, Kojima I. Regulation of the expression of follistatin in rat hepatocytes. Biochim Biophys Acta 1997;1354:204-10.
27. Vale W, Rivier J, Vaughan J, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986;321:776-9.
28. Ling N, Ying SY, Ueno N, et al. Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature 1986;321:779-82.
29. Murata M, Eto Y, Shibai H, Sakai M, Muramatsu M. Erythroid differentiation factor is encoded by the same mRNA as that of inhibin βA chain. Proc Natl Acad Sci U S A 1988;85:2434-8.
30. Ogawa Y, Schmidt DK, Nathan RM, et al. Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem 1992;267:14233-7.
31. Zhang Z, Zheng J, Zhao Y, et al. Overexpression of activin A inhibits growth, induces apoptosis, and suppresses tumorigenicity in an androgen-sensitive human prostate cancer cell line LNCaP. Int J Oncol 1997;11:727-76.
32. Ying SY, Zhang Z. Expression and localization of inhibin/activin subunits andac tivin receptors in MCF-7 cells, a human breast cancer cell line. Breast Cancer Res Treat 1996;37:151-60.
33. Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H, Mori M. Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 2003;22:75-80.
34. Kleeff J, Ishiwata T, Friess H, Buchler MW, Korc M. Concomitant over-expression of activin/inhibin β subunits and their receptors in human pancreatic cancer. Int J Cancer 1998;77:860-8.
35. Zheng W, Luo MP, Welt C, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 1998;69:23-31.
36. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409-17.
37. Leto G, Incorvaia L, Badalamenti G, et al. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis 2006;23:117-22.
38. Ogawa K, Funaba M, Mathews LS, Mizutani T. Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J Immunol 2000;165:2997-3003.
39. Maeshima K, Maeshima A, Hayashi Y, Kishi S, Kojima I. Crucial role of activin A in tubulogenesis of endothelial cells induced by vascular endothelial growth factor. Endocrinology 2004;145:3739-45.
40. Folkman J. Tumor angiogenesis: therapeutic implication. N Engl J Med 1971;285:182-6.
41. Yano S, Matsumori Y, Ikuta K, Ogino H, Doljinsuren T, Sone S. Current status and perspective of angiogenesis and anti vascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 2006;11:73-81.
42. Krneta J, Kroll J, Alves F, et al. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 2006;66:5686-95.
43. Poulaki V, Mitsiades N, Kruse FE, et al. Activin A in the regulation of corneal neovascularization and vascular endothelial growth factor expression. Am J Pathol 2004;164:1293-302.
44. Wagner K, Peters M, Scholz A, et al. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology 2004;126:1828-43.